IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...
Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL ...
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
WASHINGTON, DC—Transcatheter tricuspid valve repair with the Pascal system (Edwards Lifesciences) significantly reduces tricuspid regurgitation (TR) with durable outcomes at 1 year, according to new ...
KUALA LUMPUR, May 15 (Bernama) -- Institut Jantung Negara (IJN) has become the first hospital in Malaysia to clinically utilise the PASCAL Precision transcatheter valve repair system for patients with ...
BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results